Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Integration of Non-Communicable Disease Services within Primary Health Care

 
Introduction
The Primary Health Care Department at the Ministry of Public Health in collaboration with WHO, launched an initiative for the integration of Non-Communicable Diseases (NCD) program within Primary Health Care centers in Lebanon, in 2012. This initiative aimed at integrating a two-step early detection of Diabetes Mellitus and Hypertension as well as estimating the Total Cardiovascular Risk among beneficiaries aged 40 years and above. The model adopted in this initiative was based on the WHO’s 2012 package of Essential Non-Communicable Diseases interventions for Primary Health Care.
The two-step screening model consists of administering initially a screening tool by the health care workers whether in the setting of the health center or in the community. Step 1 consists of using this tool which is in the form of a questionnaire that tackles information related to the beneficiaries. The health care worker would then calculate the total cardiovascular risk for the beneficiary (using the WHO/International Society of Hypertension –WHO/ISH- risk prediction charts) and would refer him/her to the next step (Step 2) in case the total cardiovascular risk was greater than 10% or there was a previous history of diabetes or hypertension. Step 2 involves performing a set of laboratory tests and a referral to the treating physician for calculation of the final cardiovascular risk.
 
Development of the Non-Communicable Disease Program
The program has passed through many phases, in each phase many centers were trained on implementing and using the NCD programs tools and protocols. All the centers within the Primary Healthcare network were trained on NCD within the time period 2013 to 2017. Training sessions were done on regular basis including 25 centers per session. The training included the healthcare workers, nursing staff, administrative staff and physicians.
 
Continuous Support
In order to maintain the sustainability of the program, POINT OF CARE testing machines for NCD screening were distributed to all involved Primary Health Care centers.
Furthermore, to sustain the accuracy of the data entered daily by the centers, an NCD e module was developed by the IT MoPH department on the Health Information System to aid the centers to enter all the NCD related data and perform the calculations necessary for diagnosis of cardiovascular risks.
The MoPH encourages the Primary Health Care centers in Lebanon to organize outreach activities, events and campaigns to raise the awareness on health factors associated with cardiovascular diseases (CVDs), such as obesity, lack of physical activity and smoking (tobacco-use). MoPH provides educational material to support these activities.
 
    ...
    21
    ...
ATC Name B/G Ingredients Dosage Form Price
J01GB03 GENTAMICINE PANPHARMA G Gentamicin (sulfate) - 40mg/2ml 40mg/2ml Injectable solution 643,701 L.L
L02BG03 ANASTROZOLE BIOGARAN G Anastrozole - 1mg 1mg Tablet, coated 3,800,387 L.L
M01AB16 ARACENAC G Aceclofenac - 100mg 100mg Tablet, film coated 330,585 L.L
N01BB02 LIDOCAINE- ORBUCELL G Lidocaine HCl - 2% 2% Injectable solution 1,787,950 L.L
N05CD08 MIDAZOLAM HAMELN G Midazolam (HCl) - 5mg/ml 5mg/ml Injectable solution 561,726 L.L
P02DA01 TENIADEX G Niclosamide - 500mg 500mg Tablet 70,392 L.L
R06AD02 PROMETAL G Promethazine - 25mg 25mg Tablet 194,537 L.L
V03AF03 EUROFOLIC G Folic acid as Calcium Folinate Hydrate - 50mg/5ml 10mg/ml Injectable solution 5,305,490 L.L
A02BC01 OMEPRAL G Omeprazole - 40mg 40mg Capsule, delayed release 499,142 L.L
A10BK03 FLORIANCE 25 G Empagliflozin - 25mg 25mg Tablet, film coated 1,791,790 L.L
B05CX01 DEXTROSE G Dextrose, H2O - 5g/100ml 5g/100ml Injectable solution 188,772 L.L
C10AA05 ATOR MEDIS G Atorvastatin - 40mg 40mg Tablet, film coated 694,767 L.L
D07CC01 ZETA-CORT G Fusidic acid - 20mg/g, Betamethasone (valerate) - 1mg/g Cream 244,579 L.L
G04BE03 TOURNES G Sildenafil - 100mg 100mg Tablet 1,592,310 L.L
J01CR02 CURAM G Amoxicillin (trihydrate) - 500mg, Clavulanic Acid (potassium) - 125mg 625mg Tablet, film coated 402,189 L.L
J01GB03 GENTAMICINE PANPHARMA G Gentamicin (sulfate) - 40mg/2ml 40mg/2ml Injectable solution 643,701 L.L
L01EB01 APO-GEFITINIB G Gefitinib - 250mg 250mg Tablet 87,345,820 L.L
L02BG03 APO-ANASTROZOLE G Anastrozole - 1mg 1mg Tablet 2,615,118 L.L
M01AB16 LOFLAM G Aceclofenac - 100mg 100mg Tablet 767,334 L.L
N01BB02 LIDOCAINE PANPHARMA 2% G Lidocaine (HCl) - 20mg/ml 2% Injectable solution 3,398,578 L.L
N03AX11 TOPIRAMATE ARROW G Topiramate - 100mg 100mg Tablet, film coated 1,440,599 L.L
N05CD08 MIDAZOLAM PANPHARMA G Midazolam - 5mg/ml 5mg/ml Injectable solution 826,463 L.L
P03AB02 GAMMA BENZENE HEXACHLORIDE G Lindane - 1% 1% Shampoo 195,817 L.L
R06AD02 PROMETAL G Promethazine - 25mg 25mg Tablet 8,003,607 L.L
V03AF03 EUROFOLIC G Folic acid as Calcium Folinate Hydrate - 100mg/10ml 10mg/ml Injectable solution 5,872,592 L.L
A02BC01 RISEK G Omeprazole - 40mg 40mg Capsule, enteric coated 522,755 L.L
A07EC02 SALCROZINE G Mesalazine - 1g 1g Tablet, gastroresistant 4,073,187 L.L
B05CX01 DEXTROSE G Dextrose, H2O - 5g/100ml 5g/100ml Injectable solution 195,361 L.L
C09CA03 ANGINET G Valsartan - 160mg 160mg Tablet, film coated 544,256 L.L
C10AA05 ATORLIP 40 G Atorvastatin (calcium) - 40mg 40mg Tablet, film coated 1,484,626 L.L
    ...
    21
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025